Research Summary
Ipamorelin is a selective growth hormone secretagogue studied for stimulating GH release with minimal effect on other pituitary hormones.
Evidence profile
Human Phase 2 evidence
10 cited publications · 2 primary trials
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Beck DE et al. · International journal of colorectal disease · 2014
The study reportedIpamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated. There were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.
Gobburu JV et al. · Pharmaceutical research · 1999
The study reportedThe proposed PK/PD model provides a useful characterization of ipamorelin disposition and GH responses across a range of doses.
Lu Z et al. · Physiology & behavior · 2024 · PMID 39043357
Gouda M et al. · Animal reproduction science · 2024 · PMID 38996787
N Mohammadi E et al. · Journal of experimental pharmacology · 2020 · PMID 32801950
Gajda PM et al. · Drug testing and analysis · 2019 · PMID 30136411
Worm DJ et al. · Journal of peptide science : an official publication of the European Peptide Society · 2018 · PMID 30168238
Ferro P et al. · Drug testing and analysis · 2017 · PMID 26811125
Semenistaya E et al. · Drug testing and analysis · 2015 · PMID 25869809
Greenwood-Van Meerveld B et al. · Journal of experimental pharmacology · 2012 · PMID 27186127
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Lucid Peptides material. Citations verified against PubMed on 2026-08-09.